Preliminary findings from this ongoing study support the prognostic value of non-VHL mutations includingPBRM1, BAP1, SETD2, KDM5C, ATM, MTOR, andPTEN in primary ccRCC tumors as surrogates of earlier recurrence and potential selection for adjuvant immune checkpoint inhibition. The gene discussed is SETD2; the disease is nonpapillary renal cell carcinoma.